0
Correspondence |

Hyperimmune IV Immunoglobulin Treatment of 2009 Influenza A(H1N1)Immunoglobulin Treatment of 2009 Influenza A(H1N1) FREE TO VIEW

Beuy Joob; Viroj Wiwanitkit
Author and Funding Information

From the Sanitation 1 Medical Academic Center (Dr Joob); and the Faculty of Medicine, University of Niš (Dr Wiwanitkit); and Hainan Medical University (Dr Wiwanitikit), Haikou, China.

Correspondence: Beuy Joob, MD, Sanitation 1 Medical Academic Center, Bangkok, Thailand 10160; e-mail: beuyjoob@hotmail.com


Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2013;144(2):712. doi:10.1378/chest.13-0525
Text Size: A A A
Published online
To the Editor:

We read the article by Hung et al1 in this issue of CHEST (see page 464) on hyperimmune IV immunoglobulin (H-IVIG) treatment for 2009 influenza A(H1N1) with great interest. They concluded that “treatment of severe A(H1N1) infection with H-IVIG within 5 days of symptom onset was associated with a lower viral load and reduced mortality.”1 Use of immunoglobulin treatment seems to be a new treatment of H1N1 influenza. It is mentioned as an additional therapy to the standard antiviral treatment.2 The present report showed a good clinical outcome: clearance of symptoms. However, the concern is on the adverse effect and long-term outcome of using H-IVIG treatment. Because the present report is based on a limited number of patients, some uncommon adverse effects of using H-IVIG (such as anaphylaxis, hypotension, and rash3) might not be detected. Additionally, the issue of cost-effectiveness of this new therapeutic option should be further assessed.

References

Hung IFN, To KKW, Lee C-K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464-473.
 
Wiwanitkit V. Antiviral drug treatment for emerging swine flu. Clin Ter. 2009;160(3):243-245.
 
al-Hemsi B, McGory RW, Shepard B, et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant. 1996;10(6 pt 2):668-675.
 

Figures

Tables

References

Hung IFN, To KKW, Lee C-K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464-473.
 
Wiwanitkit V. Antiviral drug treatment for emerging swine flu. Clin Ter. 2009;160(3):243-245.
 
al-Hemsi B, McGory RW, Shepard B, et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant. 1996;10(6 pt 2):668-675.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543